Download
current uses and outcomes of hematopoietic stem cell transplantation 2013 n.
Skip this Video
Loading SlideShow in 5 Seconds..
Current Uses and Outcomes of Hematopoietic Stem Cell Transplantation 2013 PowerPoint Presentation
Download Presentation
Current Uses and Outcomes of Hematopoietic Stem Cell Transplantation 2013

Current Uses and Outcomes of Hematopoietic Stem Cell Transplantation 2013

466 Vues Download Presentation
Télécharger la présentation

Current Uses and Outcomes of Hematopoietic Stem Cell Transplantation 2013

- - - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

  1. Current Uses and Outcomes of Hematopoietic Stem Cell Transplantation 2013

  2. Location of Centers Participatingin the CIBMTR 2013

  3. Transplant Activity in the US

  4. Allogeneic Stem Cell Sources by Recipient Age

  5. Autologous Stem Cell Sources by Recipient Age

  6. Trends in Transplantsby Type and Recipient Age*

  7. Trends in Transplants by Transplant Type and Recipient Age*

  8. Indications for Hematopoietic Stem Cell Transplants in the US, 2011

  9. Indications for Hematopoietic Stem Cell Transplants for Age ≤ 20 years, in the US, 2011

  10. Allogeneic Transplants for Age ≤ 20 years, Registered with the CIBMTR

  11. Allogeneic Transplants for Age > 20 years, Registered with the CIBMTR

  12. Unrelated Donor Stem Cell Sourcesby Recipient Age

  13. Unrelated Cord Blood Transplants by AgeRegistered with the CIBMTR

  14. One-year Survival by Year of Transplant, Donor and Age, Worldwide

  15. 100-day Mortality after Autologous Transplants, 2010-2011

  16. 100-day Mortality after HLA-identical Sibling Transplants, 2010-2011

  17. 100-day Mortality after Unrelated Donor Transplants, 2010-2011

  18. Causes of Death after Autologous Transplants done in 2010-2011

  19. Causes of Death after HLA-identical Sibling Transplants done in 2010-2011

  20. Causes of Death after Unrelated Donor Transplants done in 2010-2011

  21. Allogeneic Transplants Registered with the CIBMTR

  22. Allogeneic Transplants after Reduced Intensity Conditioning, by Donor Type, Registered with CIBMTR

  23. Proportion of Allogeneic Transplants with Reduced Intensity Conditioning for Different Indications

  24. Survival after HLA-identical Sibling Donor Transplants for AML, 2001-2011

  25. Survival after Unrelated Donor Transplants for AML, 2001-2011

  26. Survival after HLA-identical Sibling Donor Transplants for AML, Age < 20 years, 2001-2011

  27. Survival after Allogeneic Transplants for MDS, 2001-2011

  28. Survival after HLA-identical Sibling Donor Transplants for ALL, Age < 20 years, 2001-2011

  29. Survival after Unrelated Donor Transplants for ALL, Age < 20 years, 2001-2011

  30. Survival after HLA-identical Sibling Donor Transplants for ALL, Age ≥ 20 years, 2001-2011

  31. Survival after Unrelated Donor Transplants for ALL, Age ≥ 20 Years, 2001-2011

  32. Survival after HLA-identical Sibling Donor Transplants for CML, 2001-2011

  33. Survival after HLA-matched Sibling Donor Hematopoietic Cell Transplants for CLL, 2001-2011

  34. Survival after Allogeneic Transplants for SAA, 2001-2011

  35. Survival after Autologous Transplants for Hodgkin Lymphoma, 2001-2011

  36. Survival after Allogeneic Transplants for Hodgkin Lymphoma, 2001-2011

  37. Survival after Autologous Transplants for Follicular Lymphoma, 2001-2011

  38. Survival after Allogeneic and HLA-identical Sibling Transplants for Follicular Lymphoma, 2001-2011

  39. Survival after Autologous Transplants for Diffuse Large B-Cell Lymphoma, 2001-2010

  40. Survival after HLA-identical Sibling Transplants for Diffuse Large B-Cell Lymphoma, 2001-2011

  41. Survival after Transplants for Mantle Cell Lymphoma, 2001-2011

  42. Survival after Transplants for Multiple Myeloma, 2001-2011